WO2023037333 - CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
National phase entry:
Publication Number
WO/2023/037333
Publication Date
16.03.2023
International Application No.
PCT/IB2022/058572
International Filing Date
12.09.2022
Title **
[English]
CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
[French]
ANTICORPS MULTISPÉCIFIQUES CD33 X VΔ2 POUR TRAITER LE CANCER
Applicants **
JANSSEN BIOTECH, INC
Inventors
DOONAN, Patrick John
LA PORTE, Sherry Lynn
SINGH, Sanjaya
PARREN, Paul Willem Henri Ida
MERAT, Sabrina Julia Louisa
ROOVERS, Robertus Cornelis
ELASHKAR, Sara Mohamed A
PHILIPPAR, Ulrike
Priority Data
63/243,493
13.09.2021
US
21202685.0
14.10.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2909 | |
| EPO | Filing, Examination, Granting | 17728 | |
| Japan | Filing, Examination, Granting | 2658 | |
| South Korea | Filing, Examination, Granting | 3211 | |
| USA | Filing, Examination, Granting | 8340 |
Total:
34,846
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to multispecific antibodies and pharmaceutical compositions comprising said antibodies, to processes for the preparation of said antibodies and to the use of said antibodies targeting CD33 and to their use in the treatment of diseases, e.g., cancer.[French]
L'invention concerne des anticorps multispécifiques et des compositions pharmaceutiques comprenant lesdits anticorps, des procédés de préparation desdits anticorps et l'utilisation desdits anticorps ciblant CD33 et leur utilisation dans le traitement de maladies, par exemple le cancer.